Subcutaneous Trastuzumab with Pertuzumab and Docetaxel in HER2-Positive Metastatic Breast Cancer: Final Analysis of MetaPHER, A Phase 3b Single-Arm Safety Study

Sherko Kümmel(Kliniken Essen-Mitte), Miguel Martín(Universidad Complutense de Madrid), Alejandro Juárez-Ramiro, Bartosz Itrych(Centralny Szpital Kliniczny), Carlo Tondini(Ospedale Papa Giovanni XXIII), Servando Cardona‐Huerta(Tecnológico de Monterrey), Zbigniew Nowecki(The Maria Sklodowska-Curie National Research Institute of Oncology), Marco Sequi(Roche (Switzerland)), Eleonora Restuccia(Roche (Switzerland)), Bogusława Karaszewska(State University of Applied Sciences in Konin), Flavia Morales-Vásquez(Secretaria de Salud), José Manuel Pérez García(Vall d'Hebron Institute of Oncology), Jacinta Abraham(Velindre NHS Trust), Erika Hitre(National Institute of Oncology), Mark Benyunes(Roche (Switzerland)), Estefanía Monturus(Roche (Switzerland))
Research Square
August 12, 2020
10.21203/rs.3.rs-57692/v1
Cited by 1

Related Papers

Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
|The Lancet|2020|1.8k
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
|New England Journal of Medicine|2019|1.4k